Cannabinoids block Covid in vitro Quebec bans cannabis from unvaccinated customers

It was in early 2020 when Lethbridge published a preprint study that showed evidence that cannabis can help with Covid. Now, an in vitro study in 2022 discovered certain cannabinoids that could block Covid spike proteins. While research in 2021 indicated that lockdowns are affecting our endocannabinoid systems. Still, Quebec’s new plan will ban patrons who are not vaccinated against the virus from buying cannabis in 2022.

Lethbridge’s research was widely shared and repeated in a Calgary Herald report. Months later, the study was published with a popular peer review. At the time, many other research projects were examining cannabis and its components for their potential to treat Covid-19. Noteworthy are the less discussed flavonoid compounds. Yet the world was stuck waiting for a vaccine and many were locked; their endocannabinoid systems and background health are slowly fading. (1-4)

Building on the evidence, the new study published by the Journal of Natural Products looked at CBDa and CBGa. They concluded that the two acidic cannabinoids block entry of the virus that Covid causes with cells in a test tube. (5) This takes smoking or vaping off the table as acidic cannabinoids are converted by heat.

… testing ground for clinical trials. This is the most reasonable way of saying that Pfizer used South Africans as guinea pigs to develop vaccines for wealthy countries …

No Covid treatments until Pfizer says

Apart from the drug Remdesivir, no other drugs were acceptable for Covid-19. This was initially due to the fact that virus variants arise when partial Covid treatments and poor vaccines generate selective immune pressure. At least that was the concern of virology professors quoted by Reuters in September 2020. In contrast, we find that scientists and media simply missed the mark after Pfizer launched a vaccine before their anti-Covid pill in 2021. (6)

Virology professor Ian Jones of Reading University in the UK spoke about Russia’s sloppy vaccine and the risk of selective pressure in a phone interview with Reuters a year and a half ago. This writer emailed Professor Jones for clarity rather than relying on antiquated information. To update, we now know that weaker immunity is simply still beneficial, even if no immunity alone can escape Sars-Cov2. Essentially, our current focus is on reducing symptoms and keeping the death rate down to manageable levels rather than eliminating the virus.

Mutations occur all the time, but evolution occurs when selection acts on these mutations and allows a “fitter” variant to dominate. One of these selection pressures is immunity.

As far as I know, all of the variants so far have shown lower levels of neutralization ability (although they don’t completely dodge it) and it is likely that this contributed to their rise. For infectious agents, immunity is certainly a factor in their development. However, it has been shown that infection with CoV can happen anyway regardless of the immunity produced by any vaccine, so the concern I and others expressed 18 months ago has been replaced with events.

Professor Ian Jones

In this case, it should be noted that the Pfizer pill is simply more selective, acutely bioavailable, and particularly patentable compared to quercetin, a flavonoid found in cannabis and other foods. Keep in mind, of course, that Pfizer is restricting access to vaccines in Africa for nefarious reasons, according to professors from Havard and Uganda. Global Health Officers have made it clear that profit drives Pfizer’s actions; If you stifle supply, you increase demand, and that means more money for big pharma. (7)

(That’s the polite way of expressing their behavior, which is focused on selling boosters to rich countries and not expanding production for the rest of the world, and in Pfizer’s case, claiming that Africa can’t handle the vaccines indescribable.) 18 /

– Dr. Tom Frieden (@DrTomFrieden) September 18, 2021

Unfortunately, Pfizer has one more reason to restrict vaccines to South Africa – it’s the testing grounds for clinical trials. That’s the most reasonable way of saying that Pfizer used South Africans as guinea pigs to develop vaccines for wealthy countries. And unfortunately, in the end, the virus will never go away if a continent or province is excluded from access to adequate health care. Hence, a continuous cycle will flourish until Pfizer runs out of Africans for clinical trials. Meanwhile, Quebec plans to ban access to cannabinoid therapy through its cannabis stores without full vaccination to block Covid.

Human rights after Quebec banned cannabis deals without Vaxx

When cannabis was legalized in Canada in 2018, the new cannabis law was brought to justice for violating Charter Section 7, the right to life and liberty. One case was filed by a disabled Ontarian named Ken Harrower. He claimed that new cannabis regulations have restricted access to medical patients due to a lack of brick and mortar stores for their needs. Further action was taken against Canada’s cannabis laws for violating Section 7 and easily won in an Alberta court. (8th)

Section 8 also protects a customer from discrimination, unjustified prohibition or restriction of doing business in Canada’s assigned territory or otherwise. So, according to case law, cannabis appears to be a drug, and restricting a patient’s access is an unjustified violation of the Charter. And access by post is not legally sufficient for many patients and shops can still serve their customers at their doorstep.

This is the case with vaccination mandates, but the charter can only be justified if the court approves it. The state and federal governments can challenge the rights of any citizen if there is a measurable threat to the community. This is another reason why the incompetent collection of Covid case data is to be assessed as criminal misconduct.

In terms of cannabis, Canada has pressured and stifled the viability of its medicinal cannabis industry. Data from Deloitte suggests Canada’s medical market will decline 50% from 2020 to 2026. Quebec, where unvaccinated people are taxed and access to cannabis is restricted from shop windows, already bans anyone from growing at home. Unfortunately, the native restriction survived a fight in the Supreme Court and remains in the province.

Full spectrum cannabis for Covid

Raphael Mechoulam was involved in a study published in 2021 that analyzed CBD against Covid-19; a bad result with a glass-half-full result. An entourage theory was supported by Mechoulam’s study, as CBD isolate was an ineffective treatment for Covid-19 compared to data produced by full profile cannabis strains. This suggests that phyto-compounds like terpenes, possibly flavonoids, and / or cannabinoid acids are a huge benefit.

Acid cannabinoids were initially not involved in Mechoulam’s study. In 2022, researchers from Oregon, USA found that CBDa and CBGa block Sars-Cov2 spike proteins, the anchor that binds to certain human receptors. (5) Another advantage of CBDa and CBGa over CBD is the inhibition of COX-2, a problematic inflammatory agent that contributes to the deadly cytokine storm. CLN continued to support the entourage argument and released a report in early 2020 highlighting the benefits of terpenes.

As reported 23 months ago, a complex mixture of terpenes from various sources reduced mortality by 50% from the deadly coronavirus known as MERS. Beyond terpenes and cannabinoids are flavonoids that block spike proteins and reduce Covid through the same mechanism of action as Pfizer’s new miracle pill. Unfortunately, flavonoids have a despicable bioavailability. But a CB2 receptor agonist like caryophyllene offers many other promises deep down in the nerves and other cells. Olorinab is a synthetic CB2 receptor agonist that Pfizer now owns after a $ 6.7 billion deal.

CBDa, CBGa, and CB2 agonists all increase a regulatory messenger (PPAR) far more effectively than CBD alone. And lipid metabolism depends on good PPAR function. In addition, Covid is a disease that completely disrupts lipid metabolism, which in part leads to a deadly cytokine storm. So should those with faint endocannabinoid tones be treated with more privileges than those vaccinated in Quebec or elsewhere because of their bad lifestyle habits?

To be honest, did you ask if Quebec and Canada ministers are focusing on their endocannabinoid tones? And after emailing them these thoughts, let us know in the comments section what you think of Quebec’s new restriction that bans a number of cannabis users.

sources

1. Bill Kaufmann. 05, 2020. Cannabis promises to block coronavirus infection: Alberta researchers. Calgary Herald.
2. Wang, B., Kovalchuk, A., Li, D., Rodriguez-Juarez, R., Ilnytskyy, Y., Kovalchuk, I. & Kovalchuk, O. (2020). In search of preventive strategies: Novel CBD-rich cannabis sativa extracts modulate ACE2 expression in COVID-19 input tissues. Aging, 12 (22), 22425-22444.
3. Kovalchuk, A., Wang, B., Li, D., Rodriguez-Juarez, R., Ilnytskyy, S., Kovalchuk, I. & Kovalchuk, O. (2021). Fighting the Storm: Could Novel Anti-TNFα and Anti-IL-6 C. sativa Strains Tame the Cytokine Storm in COVID-19? Altern, 13 (2), 1571-1590.
4. Brugnatelli, V., Facco, E. & Zanette, G. (2021). Lifestyle interventions to improve cannabinoid tone during COVID-19 lockdowns can improve compliance with prevention regulations and reduce psychophysical health complications. Limits in Psychiatry, 12, 565633.
5. van Breemen, RB, Muchiri, RN, Bates, TA, Weinstein, JB, Leier, HC, Farley, S. & Tafesse, FG (2022). Cannabinoids block the cellular entry of SARS-CoV-2 and the new variants. Journal of Natural Products, 10.1021 / acs.jnatprod.1c00946. Publish online in advance.
6. Kate Kelland. Sep. 09, 2021. The plan to launch vaccines in Russia raises concerns about virus mutation. Reuters.
7. Azfar Hossain, Stephen Asiimwe and Louise Ivers. December 2021. Claims of hesitant vaccination in African countries contradict local reality. Statistical News.
8. Crippa, J., Pacheco, JC, Zuardi, AW, Guimarães, FS, Campos, AC, Osório, FL, Loureiro, SR, Dos Santos, RG, Souza, J., Ushirohira, JM, Ferreira, RR, Mancini Costa, KC, Scomparin, DS, Scarante, FF, Pires-Dos-Santos, I., Mechoulam, R., Kapczinski, F., Fonseca, B., Esposito, D., Passos, A.,… Hallak, J. ( 2021). Cannabidiol for COVID-19 Patients With Mild to Moderate Symptoms (CANDIDATE Study): A Randomized, Double-Blind, Placebo-Controlled Clinical Study. Cannabis and cannabinoid research, 10.1089 / can.2021.0093. Publish online in advance.